/* Pinterest verifcation tag */

Latest News

Preclinical data support remyelinating potential of ABX-002

May 24, 2022 | Research

ABX-002, an experimental treatment for multiple sclerosis (MS) being developed by Autobahn Therapeutics, promoted the restoration of the myelin sheath in preclinical models of the disease, new data show. The research, which specifically tested an analog of ABX-002 called LL-341070, will be presented […]